Compare Citius Pharmaceuticals Inc (CTXR) vs Fortinet Inc (FTNT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Citius Pharmaceuticals Inc vs Fortinet Inc — how do they compare? Citius Pharmaceuticals Inc trades at $0.49 (market cap $13.79M), while Fortinet Inc trades at $189.83 (market cap $138.88B). The key difference: Fortinet Inc is far larger — about 10071.1× Citius Pharmaceuticals Inc's market cap, and Fortinet Inc is trading nearer its 52-week high, Citius Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Citius Pharmaceuticals Inc for 16 Days and Fortinet Inc for 72 Days on average.
| CTXR | FTNT | |
|---|---|---|
Market Cap | $13.79M | $138.88B |
Volume | 156,684 | 3,857,161 |
Sector | Health | Technology |
52-Week High | $1.82 | $191.27 |
52-Week Low | $0.48 | $75.23 |
Typical Hold Time | 16 Days | 72 Days |
Enterprise Value | $3.96M | $135.30B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CTXR trades at $0.5082, up 5.72% today, but remains in a bearish technical trend with negative profitability metrics. The company reported $7.1M revenue for the first nine months of 2026 from LYMPHIR sales, though net income margin remains deeply negative at -651.27%. Analyst consensus is strongly bullish with 5 buy ratings and a $5.00 price target, representing significant upside potential from current levels.
While CTXR shows promising commercial progress with its oncology drug launch, the stock faces substantial execution risks due to persistent losses and cash burn. The bullish analyst sentiment contrasts with weak fundamentals, creating a high-risk, high-reward scenario for investors betting on successful commercialization of LYMPHIR in the $400M+ CTCL market.
Fortinet (FTNT) trades at $189.10, down 1.13% today but remains near recent highs with strong technical momentum. The cybersecurity leader demonstrates robust fundamentals with 28.17% net margins and consistent earnings beats, though valuation ratios appear elevated (P/E 66.88, P/S 18.81). Recent news highlights AI security demand driving platform growth, with the company scheduled to report Q3 2026 results on October 28.
Fortinet presents growth potential through cybersecurity market leadership and AI-driven demand, but faces valuation concerns and competitive pressures. The stock's technical strength and fundamental execution support upside, though high multiples require sustained growth to justify current levels. Key risks include execution missteps and market volatility amid elevated expectations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Citius Pharmaceuticals Inc
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →About Fortinet Inc
Fortinet is a cybersecurity vendor that sells products, support, and services to small and midsize businesses, enterprises, and government entities. Its products include unified threat management appliances, firewalls, network security, and its security platform, Security Fabric. Services revenue is primarily from FortiGuard security subscriptions and FortiCare technical support. At the end of 2021, products were 38% of revenue and services were 62% of sales. The California-based company sells products worldwide.
Read more on FTNT →
